Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history
Loading CVM daily closes…
Loading price history…
Pipeline assets
Multikine
Phase 3 · ActiveModality: biological immunotherapy (mixture of natural cytokines and small biological molecules)
Aliases Leukocyte Interleukin, Injection
Partnerships Saudi Amarox Co.: exclusive Saudi Arabia distributor and local representative before the SFDA (May 2026 distribution agreement)
Indications
Locally advanced primary squamous cell carcinoma of the head and neck (SCCHN), newly diagnosed resectable, no lymph node involvement, low PD-L1 tumor expression(Phase 3)
Status note Completed 928-patient Phase 3 (IT-MATTERS) led to 212-patient confirmatory registration study in the target population; FDA indicated May 2024 the company may move forward with it and the study is underway. Breakthrough Medicine Designation application filed with the Saudi FDA August 2025. Company flags going-concern risk and dependence on future financings.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.